Conference Reports for NATAP

20th Conference on Retroviruses and Opportunistic Infections Atlanta, GA March 3 - 6, 2013 Back

Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Studies through Week 96       Reported by Jules Levin CROI 2013   K White*, ME Abram, R Kulkarni, M Rhee, J Szwarcberg, and MD Miller Gilead Sciences, Inc., Foster City, CA, US